Next-generation deep genome sequencing has only recently allowed us to quantitatively dissect the extent of heterogeneity within a tumour, resolving patterns of cancer evolution. Intratumour heterogeneity and natural selection contribute to resistance to anticancer therapies in the advanced setting. Recent evidence has also revealed that cancer evolution might be constrained. In this review, we discuss the origins of intratumour heterogeneity and subsequently focus on constraints imposed upon cancer evolution. The presence of (1) parallel evolution, (2) convergent evolution and (3) the biological impact of acquiring mutations in specific orders suggest that cancer evolution may be exploitable. These constraints on cancer evolution may help us identify cancer evolutionary rule books, which could eventually inform both diagnostic and therapeutic approaches to improve survival outcomes.
Skip Nav Destination
Review Article| February 15 2017
Constraints in cancer evolution
Nicolai J. Birkbak;
Charles Swanton an1
1UCL Cancer Institute, CRUK Lung Cancer Centre of Excellence, Paul O'Gorman Building, Huntley St., London WC1E 6DD, U.K.
2The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, U.K.
Correspondence: Charles Swanton (firstname.lastname@example.org)
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
Subramanian Venkatesan, Nicolai J. Birkbak, Charles Swanton; Constraints in cancer evolution. Biochem Soc Trans 8 February 2017; 45 (1): 1–13. doi: https://doi.org/10.1042/BST20160229
Download citation file: